Pre-eclampsia

References

Key articles

American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020 Jun;135(6):e237-60.Full text  Abstract

Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005 Mar 12;330(7491):565.Full text  Abstract

National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. June 2019 [internet publication].Full text

Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019 May;145 Suppl 1:1-33.Full text  Abstract

National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). December 2018 [internet publication].Full text

National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. Jun 2019 [internet publication].Full text

Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995 Jun 10;345(8963):1455-63. Abstract

Reference articles

1. American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020 Jun;135(6):e237-60.Full text  Abstract

2. Brown MA, Magee LA, Kenny LC, et al; International Society for the Study of Hypertension in Pregnancy (ISSHP). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice. Pregnancy Hypertens. 2018 Jul;13:291-310. Abstract

3. US Preventive Services Task Force. Screening for preeclampsia: US Preventive Services Task Force recommendation statement. JAMA. 2017 Apr 25;317(16):1661-7.Full text  Abstract

4. Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013 Oct;71(suppl 1):S18-25.Full text  Abstract

5. Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. BJOG. 2005 Jul;112(7):875-80.Full text  Abstract

6. Ngwenya S. Severe preeclampsia and eclampsia: incidence, complications, and perinatal outcomes at a low-resource setting, Mpilo Central Hospital, Bulawayo, Zimbabwe. Int J Womens Health. 2017 May 17;9:353-7.Full text  Abstract

7. Osungbade KO, Ige OK. Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. J Pregnancy. 2011;2011:481095.Full text  Abstract

8. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002 Sep;2(9):656-63. Abstract

9. Walker JJ. Pre-eclampsia. Lancet. 2000 Oct 7;356(9237):1260-5. Abstract

10. Desoye G, Hauguel-de Mouzon S. The human placenta in gestational diabetes mellitus: the insulin and cytokine network. Diabetes Care. 2007 Jul;30 Suppl 2:S120-6.Full text  Abstract

11. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005 Mar 12;330(7491):565.Full text  Abstract

12. Brew O, Sullivan MH, Woodman A. Comparison of normal and pre-eclamptic placental gene expression: a systematic review with meta-analysis. PLoS One. 2016 Aug 25;11(8):e0161504.Full text  Abstract

13. Duhig K, Vandermolen B, Shennan A. Recent advances in the diagnosis and management of pre-eclampsia. F1000Res. 2018 Feb 28;7:242.Full text  Abstract

14. Smith TA, Kirkpatrick DR, Kovilam O, et al. Immunomodulatory role of vitamin D in the pathogenesis of preeclampsia. Expert Rev Clin Immunol. 2015;11(9):1055-63.Full text  Abstract

15. de Haas S, Ghossein-Doha C, van Kuijk SM, et al. Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017 Feb;49(2):177-87. Abstract

16. MBRRACE-UK; Knight M, Bunch K, Tuffnell D, et al. Saving lives, improving mothers’ care: lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2015-17. November 2019 [internet publication].Full text

17. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. June 2019 [internet publication].Full text

18. Deen ME, Ruurda LG, Wang J, et al. Risk factors for preeclampsia in multiparous women: primipaternity versus the birth interval hypothesis. J Matern Fetal Neonatal Med. 2006 Feb;19(2):79-84. Abstract

19. Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta. 2000 Sep;21(7):597-602. Abstract

20. Hernández-Díaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009 Jun 18;338:b2255.Full text  Abstract

21. Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019 May;145 Suppl 1:1-33.Full text  Abstract

22. GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet. 2005 Jul;77(1):P127-31.Full text  Abstract

23. Lin Y, Wang L, Yan Y, et al. A meta-analysis of tumor necrosis factor-α and FAS/FASL polymorphisms with risk of pre-eclampsia. Hypertens Pregnancy. 2019 Feb;38(1):20-31. Abstract

24. Poorolajal J, Jenabi E. The association between body mass index and preeclampsia: a meta-analysis. J Matern Fetal Neonatal Med. 2016 Nov;29(22):3670-6. Abstract

25. Spradley FT. Metabolic abnormalities and obesity's impact on the risk for developing preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2017 Jan 1;312(1):R5-12.Full text  Abstract

26. Khalil A, Syngelaki A, Maiz N, et al. Maternal age and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol. 2013 Dec;42(6):634-43.Full text  Abstract

27. DoPierala AL, Bhatta S, Raja EA, et al. Obstetric consequences of subfertility: a retrospective cohort study. BJOG. 2016 Jul;123(8):1320-8. Abstract

28. Schwarze JE, Borda P, Vásquez P, et al. Is the risk of preeclampsia higher in donor oocyte pregnancies? A systematic review and meta-analysis. JBRA Assist Reprod. 2018 Mar 1;22(1):15-19.Full text  Abstract

29. Yu HF, Chen HS, Rao DP, et al. Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016 Dec;95(51):e4863.Full text  Abstract

30. Wiles K, Chappell L, Clark K, et al. Clinical practice guideline on pregnancy and renal disease. BMC Nephrol. 2019 Oct 31;20(1):401.Full text  Abstract

31. Bramham K, Briley AL, Seed PT, et al. Pregnancy outcome in women with chronic kidney disease: a prospective cohort study. Reprod Sci. 2011 Jul;18(7):623-30. Abstract

32. Palma-Reis I, Vais A, Nelson-Piercy C, et al. Renal disease and hypertension in pregnancy. Clin Med (Lond). 2013 Feb;13(1):57-62.Full text  Abstract

33. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014 Mar 18;129(11):1254-61.Full text  Abstract

34. Palmer SK, Moore LG, Young D, et al. Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 meters) in Colorado. Am J Obstet Gynecol. 1999 May;180(5):1161-8. Abstract

35. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-22.Full text  Abstract

36. Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD004659.Full text  Abstract

37. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141-6.Full text  Abstract

38. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2018 Mar;218(3):287-93.Full text  Abstract

39. Barakat R, Pelaez M, Cordero Y, et al. Exercise during pregnancy protects against hypertension and macrosomia: randomized clinical trial. Am J Obstet Gynecol. 2016 May;214(5):649. Abstract

40. Davenport MH, Ruchat SM, Poitras VJ, et al. Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis. Br J Sports Med. 2018 Nov;52(21):1367-75. Abstract

41. Hofmeyr GJ, Lawrie TA, Atallah ÁN, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2018 Oct 1;(10):CD001059.Full text  Abstract

42. World Health Organization. WHO recommendation: calcium supplementation during pregnancy for the prevention of pre-eclampsia and its complications. Geneva: World Health Organization; 2018.Full text  Abstract

43. Villar J, Abdel-Aleem H, Merialdi M, et al; World Health Organization Calcium Supplementation for the Prevention of Preeclampsia Trial Group. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol. 2006 Mar;194(3):639-49.Full text  Abstract

44. Hofmeyr GJ, Manyame S, Medley N, et al. Calcium supplementation commencing before or early in pregnancy, for preventing hypertensive disorders of pregnancy. Cochrane Database Syst Rev. 2019 Sep 16;(9):CD011192.Full text  Abstract

45. Palacios C, Kostiuk LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2019 Jul 26;(7):CD008873.Full text  Abstract

46. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol. 1988 Apr;158(4):892-8. Abstract

47. Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):e1-29.Full text  Abstract

48. Tourigny C, Rey E, Moreau J, et al. Albumin/creatinine ratio for the detection of significant proteinuria of preeclampsia in hospitalized hypertensive women. J Obstet Gynaecol Canada. 2021 May 1;43(5):576-82.

49. National Institute for Health and Care Excellence. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio). December 2018 [internet publication].Full text

50. Duhig KE, Myers J, Seed PT, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019 May 4;393(10183):1807-18.Full text  Abstract

51. Eastwood KA, Patterson C, Hunter AJ, et al. Evaluation of the predictive value of placental vascularisation indices derived from 3-dimensional power Doppler whole placental volume scanning for prediction of pre-eclampsia: a systematic review and meta-analysis. Placenta. 2017 Mar;51:89-97. Abstract

52. von Dadelszen P, Payne B, Li J, et al; PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011 Jan 15;377(9761):219-27. Abstract

53. Thangaratinam S, Allotey J, Marlin N, et al. Development and validation of Prediction models for Risks of complications in Early-onset Pre-eclampsia (PREP): a prospective cohort study. Health Technol Assess. 2017 Apr;21(18):1-100.Full text  Abstract

54. Sotiriadis A, Hernandez-Andrade E, da Silva Costa F, et al; ISUOG CSC Pre-eclampsia Task Force. ISUOG practice guidelines: role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol. 2019 Jan;53(1):7-22.Full text  Abstract

55. Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016 Apr 19;353:i1753.Full text  Abstract

56. Kuc S, Wortelboer EJ, van Rijn BB, et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv. 2011 Apr;66(4):225-39. Abstract

57. Skråstad RB, Hov GG, Blaas HG, et al. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. BJOG. 2015 Dec;122(13):1781-8.Full text  Abstract

58. Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017 Oct;50(4):492-5.Full text  Abstract

59. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. Jun 2019 [internet publication].Full text

60. van Baaren GJ, Broekhuijsen K, van Pampus MG, et al. An economic analysis of immediate delivery and expectant monitoring in women with hypertensive disorders of pregnancy, between 34 and 37 weeks of gestation (HYPITAT-II). BJOG. 2017 Feb;124(3):453-61.Full text  Abstract

61. Churchill D, Duley L, Thornton JG, et al. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestation. Cochrane Database Syst Rev. 2018 Oct 5;(10):CD003106.Full text  Abstract

62. Publications Committee, Society for Maternal-Fetal Medicine; Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol. 2011 Sep;205(3):191-8.Full text  Abstract

63. American College of Obstetricians and Gynecologists. Committee opinion no. 455: magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010 Mar;115(3):669-71.Full text  Abstract

64. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al; HYPITAT-II study group. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet. 2015 Jun 20;385(9986):2492-501. Abstract

65. Koopmans CM, Bijlenga D, Groen H, et al; HYPITAT Study Group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009 Sep 19;374(9694):979-88. Abstract

66. Cluver C, Novikova N, Koopmans CM, et al. Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term. Cochrane Database Syst Rev. 2017 Jan 15;(1):CD009273.Full text  Abstract

67. Chappell LC, Brocklehurst P, Green ME, et al. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet. 2019 Sep 28;394(10204):1181-90.Full text  Abstract

68. Hein HA. Cardiorespiratory arrest with laryngeal oedema in pregnancy-induced hypertension. Can Anaesth Soc J. 1984 Mar;31(2):210-2. Abstract

69. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 767: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2019 Feb;133(2):e174-80.Full text  Abstract

70. Shekhar S, Gupta N, Kirubakaran R, et al. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016 Jan;123(1):40-7.Full text  Abstract

71. Moodley J, Soma-Pillay P, Buchmann E, et al. Hypertensive disorders in pregnancy: 2019 national guideline. S Afr Med J. 2019 Sep 13;109(9):12723.Full text  Abstract

72. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019 Jan;133(1):e26-50. Abstract

73. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995 Jun 10;345(8963):1455-63. Abstract

74. Medicines and Healthcare products Regulatory Agency. Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy. May 2019 [internet publication].Full text

75. US Food and Drug Administration. FDA drug safety communication: FDA recommends against prolonged use of magnesium sulfate to stop preterm labor due to bone changes in exposed babies. May 2013 [internet publication].Full text

76. Kusminsky RE. Complications of central venous catheterization. J Am Coll Surg. 2007 Apr;204(4):681-96. Abstract

77. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003 Mar 20;348(12):1123-33.Full text  Abstract

78. Smith RN, Nolan JP. Central venous catheters. BMJ. 2013 Nov 11;347:f6570. Abstract

79. Reich DL. Monitoring in anesthesia and perioperative care. Cambridge: Cambridge University Press; 2011.

80. Abbott Northwestern Hospital Internal Medicine Residency. Internal jugular central venous line. 2015 [internet publication].Full text

81. Bishop L, Dougherty L, Bodenham A, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007 Aug;29(4):261-78. Abstract

82. Practice guidelines for central venous access 2020: an updated report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2020 Jan;132(1):8-43.Full text  Abstract

83. Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth. 2000 Aug;85(2):188-91.Full text  Abstract

84. Gibson F, Bodenham A. Misplaced central venous catheters: applied anatomy and practical management. Br J Anaesth. 2013 Mar;110(3):333-46.Full text  Abstract

85. Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth. 2000 Aug;85(2):192-4.Full text  Abstract

86. Conrad KP. G-protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention. Hum Reprod Update. 2016 Sep;22(5):647-64.Full text  Abstract

87. Paauw ND, Terstappen F, Ganzevoort W, et al. Sildenafil during pregnancy: a preclinical meta-analysis on fetal growth and maternal blood pressure. Hypertension. 2017 Nov;70(5):998-1006. Abstract

88. Sibley CP. Treating the dysfunctional placenta. J Endocrinol. 2017 Aug;234(2):R81-97.Full text  Abstract

89. Heida KY, Bots ML, de Groot CJ, et al. Cardiovascular risk management after reproductive and pregnancy-related disorders: a Dutch multidisciplinary evidence-based guideline. Eur J Prev Cardiol. 2016 Nov;23(17):1863-79. Abstract

90. Wang Z, Wang Z, Wang L, et al. Hypertensive disorders during pregnancy and risk of type 2 diabetes in later life: a systematic review and meta-analysis. Endocrine. 2017 Mar;55(3):809-21. Abstract

91. Benschop L, Duvekot JJ, Versmissen J, et al. Blood pressure profile 1 year after severe preeclampsia. Hypertension. 2018 Mar;71(3):491-8. Abstract

92. Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2018 Dec;125(13):1642-54.Full text  Abstract

93. Stuart JJ, Tanz LJ, Missmer SA, et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: an observational cohort study. Ann Intern Med. 2018 Aug 21;169(4):224-32. Abstract

94. Kristensen JH, Basit S, Wohlfahrt J, et al. Pre-eclampsia and risk of later kidney disease: nationwide cohort study. BMJ. 2019 Apr 29;365:l1516.Full text  Abstract

95. Khashan AS, Evans M, Kublickas M, et al. Preeclampsia and risk of end stage kidney disease: a Swedish nationwide cohort study. PLoS Med. 2019 Jul;16(7):e1002875.Full text  Abstract

96. Behrens I, Basit S, Melbye M, et al. Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study. BMJ. 2017 Jul 12;358:j3078.Full text  Abstract

97. Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women – a scientific statement from the American Heart Association. Circulation. 2021 May 4;143(18):e902-16.Full text  Abstract

98. Miller EC, Gatollari HJ, Too G, et al. Risk factors for pregnancy-associated stroke in women with preeclampsia. Stroke. 2017 Jul;48(7):1752-9.Full text  Abstract

99. Dodd JM, McLeod A, Windrim RC, et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2013 Jul 24;(7):CD006780.Full text  Abstract

100. Roberge S, Demers S, Nicolaides KH, et al. Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2016 May;47(5):548-53.Full text  Abstract

Use of this content is subject to our disclaimer